CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 824 enrolled
Drug / intervention
ciclesonide HFA 160 μgdrug
Likely dose
ciclesonide HFA 160 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01067105
NCT01067105Phase 3Completed
CompareCT.gov

A 6-Month Open-Label, Long-Term Safety Extension Study of Once Daily Ciclesonide HFA Nasal Aerosol (160 μg) in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

Sumitomo Pharma America, Inc.·interventional·Posted Feb 11, 2010·Updated Jun 13, 2012

In Brief

A Phase 3 clinical trial evaluating ciclesonide HFA 160 μg for Perennial Allergic Rhinitis. Completed, enrolled 824 participants across 44 sites.

Detailed Summary

6-month safety extension study in subjects who have completed Study 060-633 (NCT00953147). Evaluating the long-term safety of ciclesonide HFA nasal aerosol 160 μg administered once-daily in patients with Perennial Allergic Rhinitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPerennial Allergic Rhinitis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 11, 2010
Enrollment StartFeb 1, 2010
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.4 years ago

Interventions

ciclesonide HFA 160 μgdrug

ciclesonide HFA 160 μg once daily